Antibodies against the Plasmodium falciparum glutamate-rich protein from naturally exposed individuals living in a Brazilian malaria-endemic area can inhibit in vitro parasite growth

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue SUPPL. 1, 2011, Pages 34-43

  Pratt Riccio, Lilian Rose ^a   Bianco Junior, Cesare ^a   Totino, Paulo Renato Rivas ^a   Perce da Silva, Daiana de Souza ^a   Silva, Luciene Aquino ^a   Riccio, Evelyn Kety Pratt ^a   Ennes Vidal, Vítor ^a   Neves Ferreira, Ana Gisele Costa ^a   Perales, Jonas ^a   da Rocha, Surza Lucia Gonçalves ^a   Dias da Silva, Fabrício ^a   Ferreira da Cruz, Maria de Fátima ^a   Daniel Ribeiro, Cláudio Tadeu ^a   de Oliveira Ferreira, Joseli ^a   Theisen, Michael ^b   de Moura Carvalho, Leonardo José ^a   Banic, Dalma Maria ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Antibodies; Biological activity; GLURP; Growth inhibition; Malaria; Plasmodium falciparum

Indexed keywords

PLASMODIUM FALCIPARUM;

EID: 80051735382     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000900005     Document Type: Article

References (68)

1. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66: 641-648.
2. Aribot G, Rogier C, Sarthou JL, Trape JF, Balde AT, Druilhe P, Roussilhon C 1996. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg 54: 449-457.
3. Bolad A, Berzins K 2000. Antigenic diversity of Plasmodium falciparum and antibody-mediated parasite neutralization. Scand J Immunol 52: 233-239.
4. Borre MB, Dziegiel M, Hogh B, Petersen E, Rieneck K, Riley E, Meis JF, Aikawa M, Nakamura K, Harada M, Wind A, Jacobsen PH, Cowland J, Jepsen S, Axelsen NH, Vuust J 1991. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the pre-erythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 49: 119-131.
5. Boudin C, Chumpitazi B, Dziegiel M, Peyron F, Picot S, Hogh B, Ambroise-Thomas P 1993. Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso.J Clin Microbiol 31: 636-641.
6. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not, on their own, inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
7. Bouharoun-Tayoun H, Druilhe P 1992. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60: 1473-1481.
8. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P 1995. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182: 409-418.
9. Camargo EP, Alves F, Pereira-da-Silva LH 1999. Symptomless Plasmodium vivax infections in native Amazonians. Lancet 353: 1415-1416.
10. Castilla RE, Sawyer DO 1993. Malaria rates and fate: a socioeconomic study of malaria in Brazil. Soc Sci Med 37: 1137-1145.
11. Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS, Heywood PF, Alpers MP, Stevenson A, Clancy R 1986. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. Am J Trop Med Hyg 35: 3-15.
12. Chimma P, Roussilhon C, Sratongno P, Ruangveerayuth R, Pattanapanyasat K, Perignon JL, Roberts DJ, Druilhe P 2009. A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria. PLoS Pathog 5: e1000631.
13. Clark IA, Cowden WB, Butcher GA 1990. TNF and inhibition of growth of Plasmodium falciparum. Immunol Lett 25: 175-178.
14. Cohen S, Butcher GA, Crandall RB 1969. Action of malarial antibody in vitro. Nature 223: 368-371.
15. Cohen S, McGregor A, Carrington S 1961. Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
16. Coura JR, Suárez-Mutis M, Ladeia-Andrade S 2006. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection - A review. Mem Inst Oswaldo Cruz 101: 229-237.
17. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, Hviid L 2000. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 181: 1202-1205.
18. Dziegiel M, Rowe P, Bennett S, Allen SJ, Olerup O, Gottschau A, Borre M, Riley EM 1993. Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect Immun 61: 103-108.
19. Galamo CD, Jafarshad A, Blanc C, Druilhe P 2009. Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele specific manner by monocyte-mediated antibody-dependent cellular inhibition. J Infect Dis 199: 1151-1154.
20. Good MF, Stanisic D, Xu H, Elliott S, Wykes M 2004. The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol Rev 201: 254-267.
21. Greenwood BM, Bradley AK, Greenwood AM, Byass P, Jammeh K, Marsh K, Tulloch S, Oldfield FS, Hayes R 1987. Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med Hyg 81: 478-486.
22. Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, Bolad A, Berzins K, Corradin G, Leroy O, Theisen M, Sauerwein RW 2007. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 25: 2930-2940.
23. Hogh B, Marbiah NT, Petersen E, Dolopaye E, Willcox M, Björkman A, Hanson AP, Gottschau A 1993. Classification of clinical falciparum malaria and its use for the evaluation of chemosuppression in children under six years of age in Liberia, west Africa. Acta Trop 54: 105-115.
24. Hogh B, Petersen E, Dziegiel M, David K, Hanson A, Borre M, Holm A, Vuust J, Jepsen S 1992. Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am J Trop Med Hyg 46: 307-313.
25. Hviid L, Reimert CM, Theander TG, Jepsen S, Bendtzen K 1988. Recombinant human tumour necrosis factor is not inhibitory to Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 82: 48-49.
26. Jensen JB, Boland MT, Akood M 1982. Induction of crisis forms in cultured Plasmodium falciparum with human immune serum from Sudan. Science 216: 1230-1233.
27. Khusmith S, Druilhe P 1983. Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect Immun 41: 219-223.
28. Lambros C, Vanderberg JP 1979. Syncronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65: 418-420.
29. Lundquist R, Nielsen LK, Jafarshad A, SoeSoe D, Christensen LH, Druilhe P, Dziegiel MH 2006. Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun 74: 3222-3231.
30. Lunel F, Druilhe P 1989. Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect Immun 57: 2043-2049.
31. Luty AJ, Mayombo J, Lekoulou F, Mshana R 1994. Immunologic responses to soluble exoantigens of Plasmodium falciparum in Gabonese children exposed to continuous intense infection. Am J Trop Med Hyg 51: 720-729.
32. Lyon JA, Thomas AW, Hall T, Chulay JD 1989. Specificities of antibodies that inhibit merozoite dispersal from malaria-infected erythrocytes. Mol Biochem Parasitol 36: 77-85.
33. Marques AC 1987. Human migration and the spread of malaria in Brazil. Parasitol Today 3: 166-170.
34. Marsh K, Snow RW 1999. Malaria transmission and morbidity. Parassitologia 41: 241-246.
35. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, Williams TN, Marsh K, Beeson JG 2008. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS ONE 3: e3571.
36. McGregor A, Carrington SP 1963. Treatment of east African P. falciparum malaria with west African human gamma-globulin. Trans R Soc Trop Med Hyg 57: 170-175.
37. McGregor IA 1974. Mechanisms of acquired immunity and epidemiological patterns of antibody responses in malaria in man. Bull World Health Organ 50: 259-266.
38. McGregor IA 1987. Malarial immunity: current trends and prospects. Ann Trop Med Parasitol 81: 647-656.
39. Muniz-Junqueira MI, dos Santos-Neto LL, Tosta CE 2001. Influence of tumor necrosis factor-alpha on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell Immunol 208: 73-79.
40. Ndungu FM, Bull PC, Ross A, Lowe BS, Kabiru E, Marsh K 2002. Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol 24: 77-82.
41. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
42. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P 2000. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68: 2617-2620.
43. Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, Daniel-Ribeiro CT 2010. Malaria in Brazil: an overview. Malar J 9: 115.
44. Perkins ME 1991. Approaches to study merozoite invasion of erythrocytes. Res Immunol 142: 662-665.
45. Pouvelle B, Gysin J 1997. Presence of the parasitophorous duct in Plasmodium falciparum and P. vivax parasitized Saimiri monkey red blood cells. Parasitol Today 13: 357-361.
46. Pouvelle B, Spiegel R, Hsiao L, Howard RJ, Morris RL, Thomas AP, Taraschi TF 1991. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 353: 73-75.
47. Prata A, Urdaneta M, McGreevy PB, Tada MS 1998. Infrequency of asymptomatic malaria in an endemic area in Amazonas Brazil. Rev Inst Med Trop Sao Paulo 21: 51-54.
48. Pratt-Riccio LR, Lima-Junior JC, Carvalho LJ, Theisen M, Espíndola-Mendes EC, Santos F, Oliveira-Ferreira J, Goldberg AC, Daniel-Ribeiro CT, Banic DM 2005. Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria. Am J Trop Med Hyg 73: 1096-1103.
49. Reese RT, Langreth SG, Trager W 1979. Isolation of stages of the human parasite Plasmodium falciparum from culture and from animal blood. Bull World Health Organ 57 (Suppl. 1): 53-61.
50. Rodrigues AF, Escobar AL, Souza-Santos R 2008. Spatial analysis and determination of malaria control areas in the state of Rondônia. Rev Soc Bras Med Trop 41: 55-64.
51. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, Foucault C, Chongsuphajaisiddhi T, Druilhe P 1991. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45: 297-308.
52. Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure Balde A, Diatta B, Seignot P, Roussilhon C 1997. Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect Immun 65: 3271-3276.
53. Shi YP, Sayed U, Qari SH, Roberts JM, Udhayakumar V, Oloo AJ, Hawley WA, Kaslow DC, Nahlen BL, Lal AA 1996. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 64: 2716-2723.
54. Shi YP, Udhayakumar V, Oloo AJ, Nahlen BL, Lal AA 1999. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg 60: 135-141.
55. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P 2004. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72: 247-252.
56. Stevenson MM, Tam MF, Nowotarski M 1990. Role of interferon-gamma and tumor necrosis factor in host resistance to Plasmodium chabaudi AS. Immunol Lett 25: 115-121.
57. Stevenson MM, Tam MF, Wolf SF, Sher A 1995. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J Immunol 155: 2545-2556.
58. Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M 2000. Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 111: 123-130.
59. Taverne J, Tavernier J, Fiers W, Playfair JH 1987. Recombinant tumour necrosis factor inhibits malaria parasites in vivo but not in vitro. Clin Exp Immunol 67: 1-4.
60. Taylor RR, Allen SJ, Greenwood BM, Riley EM 1998. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 58: 406-413.
61. Theisen M, Dodoo D, Toure-Balde A, Soe S, Corradin G, Koram KK, Kurtzhals JA, Hviid L, Theander T, Akanmori B, Ndiaye M, Druilhe P 2001. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 69: 5223-5229.
62. Theisen M, Soe S, Brunstedt K, Follmann F, Bredmose L, Israelsen H, Madsen SM, Druilhe P 2004. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 22: 1188-1198.
63. Theisen M, Soe S, Jessing SG, Okkels LM, Danielsen S, Oeuvray C, Druilhe P, Jepsen S 2000. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 19: 204-212.
64. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, Jepsen S, Druilhe P 1998. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 66: 11-17.
65. Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B 1995. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 2: 30-34.
66. Totino PR, Daniel-Ribeiro CT, Corte-Real S, Ferreira-da-Cruz MF 2008. Plasmodium falciparum: erythrocytic stages die by autophagic-like cell death under drug pressure. Exp Parasitol 118: 478-486.
67. Trager W, Jensen JB 1976. Human malaria parasites in continuous culture. Science 193: 673-675.
68. WHO - World Health Organization 2010. World Malaria Report, WHO, Geneve, 238 pp.